Insmed (INSM) is a biopharmaceutical company with strong momentum.
Shares are trading at new 20-year highs.
INSM has surged 128% over the past year.
Analysts expect robust revenue and earnings growth, but opinions are mixed, with some cautioning the stock is overvalued.
Valued at $34.3 billion, Insmed (INSM) is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, a treatment for rare lung conditions.
Insmed is also focused on the development of INS1009, an inhaled treatment for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. INSM checks those boxes. Since the Trend Seeker signaled a new “Buy” on Oct. 1, the stock has gained 10.12%.
INSM Price vs. Daily Moving Averages:
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
INSM hit a 20-year high of $162.80 in morning trading on Oct. 8.
INSM has a Weighted Alpha of +126.78.
Insmed has an 100% “Buy” opinion from Barchart.
The stock gained 127.29% over the past year.
Insmed has its Trend Seeker “Buy” signal intact.
INSM has made 6 new highs and gained 10.59% in the last month.
Relative Strength Index (RSI) is at 76.32.
There’s a technical support level around $158.60.
$34.3 billion market capitalization.
Revenue is projected to grow 29.95% this year and another 124.91% next year.
Earnings are estimated to increase by 0.62% this year and an additional 34.92% next year.
Story Continues
